As of January 22, 2025, OmniAb (OABI) has a market cap of $0.39 billion USD. According to our data, OmniAb is ranked No.6418 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.39 B |
-9.60%
|
Dec 31, 2024 | $0.43 B |
-42.63%
|
Dec 29, 2023 | $0.75 B |
71.39%
|
Dec 30, 2022 | $0.44 B |
-64.00%
|
Dec 31, 2021 | $1.21 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Ionis Pharmaceuticals
IONS
|
$5.13 B |
-0.000 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Market Cap | = | OABI Stock Price | * | OABI Shares Outstanding |
= | $3.20 | * | 0.12 B | |
= | $0.39 B |